Clinical case: therapeutic approach for metastatic HR+/HER2- breast cancer

Abstract

Breast cancer has the highest incidence among women worldwide. In the era of precision medicine and with the new therapeutic approaches we observe better survival rates. In this article we report a case from the real clinical practice for a patient with metastatic HR+/HER2-breast cancer and review the therapeutic decisions in this patients group.